McKinsey had been accused of aiding drug manufacturers in devising deceptive marketing strategies and increasing the sales of opioid painkillers, thereby exacerbating the opioid crisis, Reuters noted. 

The settlements, still awaiting a judge's approval, were disclosed in federal court documents filed in San Francisco. 

This payment is in addition to the $641.5 million that McKinsey had previously paid to address claims from state attorneys-general.

In these settlements, McKinsey has agreed to pay $207 million to address claims brought by counties and municipalities and an additional $23 million to resolve claims made by public school districts.

In a statement, McKinsey emphasized that it had ceased offering advice on any opioid-related business activities in 2019.